Clinical Trials

A Phase III Randomized, Double-Blind Study of Maintenance Therapy with
CC-5013 or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma

An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia

A Randomized Phase II Study of Three Fludarabine/Antibody Combinations for Patients with Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia

Dose Escalation and Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60-75 Years

Phase II Study of Maintenance Therapy with Decitabine Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients with AML < 60 Years

A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) or Placebo in Newly Diagnosed Patients
< 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML)

A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer

A Phase III Double Blind Trial of Oral Duloxetine for Treatment of Pain
Associated with Chemotherapy-Induced Peripheral Neuropathy (CIPN)

AML Companion-Novel markers

Combination Cisplatin, Etoposide and Sunitinib for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/II Study

A Randomized Phase III Trial of Adjuvant Therapy in Early Stage Non-Small Cell Lung Cancer Evaluating the Potential Utility of a Genomic Prognostic Model to Identify Patients as Candidates for Adjuvant Chemotherapy

A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non-Small Cell Lung Cancer

Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced,
Stage IIIB/IV Non-Small Cell Lung Cancer

Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide

A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed plus Sunitinib in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer

A Randomized Phase III Double Blind Trial Evaluating Selective Cox-2 Inhibition In Cox-2 Expressing Advanced Non-Small Cell Lung Cancer

Randomized Phase II Study of Maintenance Pemetrexed versus Observation for Patients with Malignant Pleural Mesothelioma without Progression after
First-Line Chemotherapy

Temp clos 1/21/09
Age 65-69 cohort closed 6/9/08
Development of a Geriatric Assessment Measure for Older Patients with Cancer

Cyclophosphamide and Doxorubicin (CA 4 vs 6 cycles) versus Paclitaxel (4 vs 6 cycles) as Adjuvant Therapy for Women with Node-Negative Breast Cancer: A 2x2 Factorial Phase III Randomized Study

Endocrine Therapy with or without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant with or without Lapatinib (GW572016) for Postmenopausal Women with Hormone Receptor Positive Advanced Breast Cancer

A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone
Combined with Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer

Endocrine Therapy in Combination with anti-VEGF Therapy: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab For Women with Hormone Receptor-Positive Advanced Breast Cancer

Randomized Phase III Trial of Paclitaxel Combined with Trastuzumab, Lapatinib or Both as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer

Randomized Phase II 2x2 Factorial Trial of the Addition of Carboplatin and/or Bevacizumab To Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer

Phase III Randomized Study of R-CHOP vs Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas